Ger­man can­cer biotech BioN­Tech rais­es a mam­moth $325M in lat­est round, bring­ing to­tal haul to $1.4B+

With sev­en clin­i­cal as­sets, a string of key part­ner­ships with ti­tans of the phar­ma­ceu­ti­cal in­dus­try and whis­pers about a po­ten­tial IPO, Ger­man can­cer drug de­vel­op­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER